Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

We are at a turning point in the fight against Alzheimer’s disease with the emergence of disease-modifying therapies for ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Blood biomarkers at disease onset may help predict relapse-associated worsening and progression independent of relapse ...

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

Motor neuron diseases are a group of progressive and ultimately fatal neurodegenerative disorders of the motor system, ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Friday approved arimoclomol (Miplyffa ...

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...